Evidence map›Paper›PMID 32035274›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020

Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.

John E Levine, Joseph H Antin, Carl E Allen, Lauri M Burroughs, Kenneth R Cooke, Steven Devine, Helen Heslop, Ryotaro Nakamura, Julie An Talano, Gregory Yanik and 1 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. CXCR6Frontiers in immunology · 2022
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

John E LevineTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: john.levine@mssm.edu.
Joseph H AntinDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Carl E AllenTexas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
Lauri M BurroughsFred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington; Seattle Children's Hospital, Seattle, Washington.
Kenneth R CookeSidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Steven DevineCenter for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
Helen HeslopCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
Ryotaro NakamuraDepartment of Hematology/HCT, City of Hope, Duarte, California.
Julie An TalanoDepartment of Pediatric Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Gregory YanikMichigan Medicine, University of Michigan, Ann Arbor, Michigan.
Nancy DiFronzoNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Funding

Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
City of Hope Core Clinical Center for the Blood and Marrow Transplant Clinical Trials NetworkUG1HL069278 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI RYOTARO NAKAMURA · 2017 to 2026
$2.2M
Targeting HIV and EBV Antigens in Patients with HIV LymphomaUG1HL108945 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Catherine M. Bollard, HELEN E HESLOP · 2017 to 2026
$2.1M
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials NetworkUG1HL138645 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JOHN LEVINE · 2017 to 2026
$1.9M
Blood & Marrow Clinical Trials Network - Hutchinson Center Core Clinical SitU10HL069246 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI APPELBAUM, FREDERICK · 2011 to 2016
$1.1M
NHLBI NIH HHS U10 HL069246NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069278NHLBI NIH HHS UG1 HL108945NHLBI NIH HHS UG1 HL138645
6 · The paper itself

Abstract

Nonmalignant blood diseases such as bone marrow failure disorders, immune dysregulation disorders, and hemoglobinopathies often lead to shortened life spans and poor quality of life. Many of these diseases can be cured with allogeneic hematopoietic cell transplantation, but patients are often not offered the procedure because of perceived insufficient efficacy and/or excess toxicity. In 2018, the Blood and Marrow Transplant Clinical Trials Network convened a task force to identify the most urgently needed yet feasible clinical trials with potential to improve the outcomes for patients with nonmalignant diseases. This report summarizes the task force discussions and specifies the network plans for clinical trial development for nonmalignant blood diseases.

Indexed as

Hematologic DiseasesHematopoietic Stem Cell TransplantationBone MarrowHumansQuality of LifeTransplantation ConditioningBone marrow failureNonmalignantThalassemiaTransplantation

Identifiers

PMID32035274
PMCPMC8062984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.